Zeneca profits pass pounds 1bn mark
Wednesday 12 March 1997
The yardsticks by which analysts measured the group's performance were at the upper end of its sector but not above it, he said. "Most of the share price is justified on fundamentals and contains no bid speculation within it," he claimed.
Despite news of a 15 per cent rise in underlying profits before exceptionals to pounds 1.01bn for 1996, the shares fell from the all-time peak hit on Monday, dropping 42p to pounds 18.605. Dealers blamed profit-taking after their strong performance this year and worries that Zeneca had only one drug in its late-stage development pipeline.
But the group reiterated its aim of achieving average annual earnings growth of 15 per cent over the next five years by building a leading position in anti-cancer drugs and certain agrochemicals, while enhancing its position in other drug areas. Sir David attempted to calm fears about the group's Macclesfield plant, which manufactures Zoladex, the big-selling anti-cancer drug, where the US Food and Drug Administration has identified problems with the manufacturing process. Sir David said 20 inspections of the plant had been completed by a variety of regulators over the past 12 months. "We are confident the few remaining outstanding issues can be resolved with the FDA to their satisfaction and we hope these issues will be resolved by the end of the month," he said.
The group said it had 18 new products under development, excluding the Zomig anti-migraine treatment acquired from Glaxo last year, which has won UK approval, and the Seroquel schizophrenia treatment due for launch this year. Pharmaceuticals profits grew 10 per cent to pounds 757m, or 6 per cent excluding exchange movements, but Zeneca warned margins would continue to be constrained by the development and marketing costs of new products. The group plans to raise its US sales force from 1,200 to nearly 2,000 this year.
Zestril, the group's heart drug which goes off patent in 2001, grew sales 11 per cent to pounds 547m in 1996, while Zoladex was up 28 per cent at pounds 333m.
Operating losses in the seeds business, now part of a joint venture with a Dutch group, were cut from pounds 48m to pounds 3m. Meanwhile, restructuring of the speciality chemicals operations, shorn of the specialty inks and textile colours arms last year, pushed profits up a quarter to pounds 70m.
Investment column, page 20
- 1 Migrant crisis: Greek soldier saved 20 people singlehandedly off Rhodes beach
- 2 Sofyen Belamouadden murder: The inside story of a crime that horrified Britain
- 3 Company breaks open Apple Watch to discover what it says is 'planned obsolescence'
- 4 Aaron and Melissa Klein: Oregon anti-gay bakers ordered to pay $135,000 after refusing to make cake for same-sex wedding
- 5 UK weather: Britain braced for snow as arctic air mass moves in
Migrant crisis: Greek soldier saved 20 people singlehandedly off Rhodes beach
Ian Brady: Moors murderer announces his support for Ukip and the SNP
Aaron and Melissa Klein: Oregon anti-gay bakers ordered to pay $135,000 after refusing to make cake for same-sex wedding
UK weather: Britain braced for snow as arctic air mass moves in
Bali Nine executions in Indonesia: Death row British grandmother Lindsay Sandiford says she 'just wants to get it over with'
General Election 2015: Chuka Umunna on the benefits of immigration, humility – and his leader Ed Miliband
The sickening truth about food banks that the Tories don't want you to know
Migrant boat disaster: Ukip candidate mocks victims in sickening Twitter post
Nigel Farage wants the BBC to stop making programmes like Doctor Who, Strictly Come Dancing, and Top Gear
Global warming: Scientists say temperatures could rise by 6C by 2100 and call for action ahead of UN meeting in Paris
General Election 2015: Britain would become a 'communist dictatorship' under Ed Miliband and Nicola Sturgeon, claims wife of Michael Gove
iJobs Money & Business
£20000 - £22500 per annum + OTE £30K: SThree: SThree Group have been well esta...
£24000 - £26000 per annum + benefits : Ashdown Group: A highly successful, glo...
£50000 - £55000 per annum: Ashdown Group: Business Analyst - Financial Service...
£18000 - £23000 per annum + OTE £45K: SThree: At SThree, we like to be differe...